top of page
Alex M. Bailey, PhD
Chief Operating Officer
Dr. Alex Bailey is Co-CEO and Chief Operating Officer of Tern Therapeutics. Prior to cofounding Tern Therapeutics, Dr. Bailey served as Head of Early Program and Portfolio Development at REGENXBIO Inc., where he led and championed programs in CNS & rare ocular disease, including MPS I, MPS II, CLN2 Batten Disease, and several early-stage preclinical assets. He also brings 10+ years’ experience in global regulatory strategy supporting all phases of development, including strategic roles at the Center for Biologics Evaluation and Research (CBER) within the US FDA. Dr. Bailey completed his Ph.D. in Biomedical Engineering from the University of Virginia.
123-456-7890
bottom of page